Table 2 Thromboembolism characteristics.
1st TEE Frequency (%) | 2nd TEE Frequency (%) | |
|---|---|---|
N | 32 | 14 |
Median Days to Diagnosis of TEE from cGVHD (Range), (IQR) | 233.5 (12–2050), (84.5–599) | 715.5 (19–2137), (459–1139) |
cGVHD Disease Status at TEE Event | ||
Inactive | 5 (16%) | 4 (29%) |
Active | 27 (84%) | 10 (71%) |
Type and Location of TEE | ||
PE | 6 (19%) | 2 (14%) |
DVT | 26 (81%) | 12 (86%) |
LE Left | 9 | 3 |
LE Right | 7 | 2 |
LE Bilateral | 1 | 0 |
UE Left | 4 | 2 |
UE Right | 4 | 5 |
IVC | 1 | 0 |
Occlusive DVT | 16 (61%) | 4 (33%) |
UE Catheter Related DVT | 5 (19%) | 4 (33%) |
Lab values at TEE Diagnosis | ||
Median (range), (IQR) | ||
WBC (x109/L) | 7.1 (0.6–21.2), (4.3–11.2) | 6.7 (3.3–11.1), (5.2–9.3) |
Absolute neutrophil count (x109/L) | 4.3 (0.6–14.6), (3.5–7.6) | 4.3 (1.4–9.2), (3.5–7.2) |
Absolute lymphocyte count (x109/L) | 1.0 (0–5.2), (0.5–1.8) | 1.3 (0.3–9.5), (0.9–1.6) |
Absolute eosinophil count (x109/L) | 0 (0–5.4), (0–0.1) | 0.1 (0–0.7), (0–0.3) |
Hemoglobin mg/dl | 11.2 (7.4–15.3), (9.9–13.0) | 12.0 (8.7–16.1), (10.5–14.4) |
Platelet (x109/L) | 112 (8–346), (57–174) | 136 (38–326), (61–184) |
Lactate dehydrogenase U/L | 437 (98–1122), (311–806) | 384 (311–457) |
Albumin | 3.2 (1.5–4.2), (2.7–3.5) | 3.1 (1.6–3.6), (2.5–3.4) |
Immunosuppression Medications at and 60 days prior to TEE Number (proportion) | ||
Corticosteroids | 28 (88%) | 10 (71%) |
Prednisone Dose equivalent mg/kg/day (averaged over 60 days prior to TEE); Median (range), (IQR) | 0.3 (0.1–1.64), (0.2–0.5) | 0.2 (0.04–1.6), (0.07–0.31) |
Budesonide | 3 (9%) | 2 (14%) |
Sirolimus | 16 (50%) | 4 (29%) |
MMF | 1 (3%) | 0 |
Rituximab | 2 (6%) | 0 |
CNI | 5 (16%) | 2 (14%) |
TNF-inhibitor | 1 (3%) | 1 (7%) |
ECP | 2 (6%) | 1 (7%) |
IVIG | 11 (34%) | 3 (21%) |
Immunomodulatory Drugs | 1 (3%) | 0 |
Erythropoietin/Thrombopoietin | 2 (6%) | 0 |
Ibrutinib or ruxolitinib | 2 (6%) | 3 (21%) |
Antiplatelet therapy (Aspirin) | 3 (9%) | 3 (21%) |
